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Abstract
The classical crystal structure of insulin was determined in 1969 by D.C. Hodgkin and colleagues 
following a 35-year program of research. This structure depicted a hexamer remarkable for its self-
assembly as a zinc-coordinated trimer of dimer. Prominent at the dimer interface was an “aromatic 
triplet” of conserved residues at consecutive positions in the B chain: PheB24, PheB25 and TyrB26. 
The elegance of this interface inspired the Oxford team to poetry: “A thing of beauty is a joy 
forever” (John Keats as quoted by Blundell, T.L., et al. Advances in Protein Chemistry 26:279–
286 (1972)). Here, we revisit this aromatic triplet in light of recent advances in the structural 
biology of insulin bound as a monomer to fragments of the insulin receptor. Such co-crystal 
structures have defined how these side chains pack at the primary hormone-binding surface of the 
receptor ectodomain. On receptor binding, the B-chain β-strand containing the aromatic triplet 
(residues B24-B28) detaches from the α-helical core of the hormone. Whereas TyrB26 lies at the 
periphery of the receptor interface and may functionally be replaced by a diverse set of 
substitutions, PheB24 and PheB25 engage invariant elements of receptor domains L1 and αCT. 
These critical contacts were anticipated by the discovery of diabetes-associated mutations at these 
positions by D.F. Steiner and his colleagues at the University of Chicago. Conservation of PheB24, 
PheB25 and TyrB26 among vertebrate insulins reflects the striking confluence of structure-based 
evolutionary constraints: foldability, protective self-assembly and hormonal activity.
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1 | INTRODUCTION
Insulin has provided an enduring model for studies in protein chemistry and cell biology 
virtually since the hormone’s landmark discovery in Toronto in 1921 [1]. The sequence of 
bovine insulin, the first protein sequence to be determined [2, 3], established that this class 
of biological heteropolymers in fact had specific sequences—and so made concrete the 
concept of a genetic code [4]. Insulin was the second protein to be crystallized (after urease) 
[5, 6] and provided the first example of protein crystallization as a process that in itself can 
confer pharmacologic advantage (for review, see [7]). Efforts to determine the three-
dimensional (3D) structure of insulin began in 1934 in the graduate studies of D.C. Hodgkin 
(then at Cambridge University) [6, 8]. These studies came to fruition in 1969 at the 
University of Oxford with the first crystal structure of a peptide hormone [9, 10]. It is fitting 
to begin this contribution, written in honor of the late Prof. Donald F. Steiner, at the point of 
intersection between his laboratory at the University of Chicago with the Hodgkin 
laboratory.
In an issue dedicated to Prof. Steiner, it is fitting to include a structural perspective as his 
studies integrated structure with enzymology, cell biology, and pathophysiology [11, 12]. 
His faculty career began in the 1960s, a decade of transformational discovery in molecular 
endocrinology. The first half of this decade, for example, witnessed international efforts to 
develop methods for the total chemical synthesis of insulin [13]. Major programs were led 
by P.G. Katsoyannis at the University of Pittsburg [14], by H. Zahn in Wool Institute of 
Aachen, German [15] and by the late Niu Jingyi and his colleagues at the Institute of 
Biochemistry, Academia Sinica (Shanghai) [16]. The success of these programs highlighted 
in the breach a seeming paradox posed by the low yields of insulin chain combination. 
Although the isolated A- and B chains contained sufficient information to direct formation 
of the three specific disulfide bridges identified by Sanger (cystines A7-B7, A6-A11 and 
A20-B19) [17], the reaction was dominated by side reactions leading to cyclic chains and 
peptide aggregates, including what is now understood to be peptide fibrils [18–21]. This 
critical barrier to chemical synthesis raised the central question of how efficiency of native 
disulfide pairing might be achieved in the biosynthesis of insulin in the specialized 
endoplasmic reticulum (ER) of pancreatic β-cells [22–24].
Such was the context for the seminal discovery of a single-chain insulin precursor by Steiner 
and Philip E. Oyer in 1967 [22, 23]. Designated proinsulin, the precursor contains a 
connecting peptide between the C-terminal residue of the B chain (ThrB30 in human insulin) 
and N-terminal residue of the A chain (conserved as GlyA1). The discovery of proinsulin and 
the C peptide quickly found medical application through development of 
radioimmunoassays (RIAs) to probe insulin secretory capacity in normal and pathological 
states, including residual β-cell function in patients with Type 1 diabetes mellitus (T1DM), 
β-cell failure in long-established Type 2 DM (T2DM) and inappropriate insulin secretion in 
β-cell neoplasia (insulinoma) (for review, see [25]). Cellular mechanisms ensuring the 
fidelity of disulfide pairing and their perturbation in a monogenic DM syndrome due to toxic 
misfolding of variant proinsulins are reviewed in an accompanying article in this issue by M. 
Liu et al. [26].
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The discovery of proinsulin led to exchange of visitors between Chicago and Oxford, 
stimulated by the determination of the crystal structure of the zinc insulin hexamer in 1969 
and at increasing resolution in 1971 [9, 10]. These years preceded the development of 
computer-graphics systems for visualization of protein structures. Intuition was facilitated 
through construction of physical models, hand-built in the first instances.
Such was the collegial respect between Professors Hodgkin and Steiner that one of these rare 
early models of the insulin monomer (now classified as a T-state protomer of the T6 
hexamer) was given to the Chicago laboratory, hand-delivered by a student visiting from 
Oxford. For more than 40 years this model assumed pride of place in Don’s office (Figure 
1). Inset at upper right are pictures of Professors Hodgkin and Steiner holding corresponding 
models.
Since 1969, the structure of insulin has been determined in a variety of crystal forms [27–
31], in solution by NMR methods [32–39], and most recently, in complexes with fragments 
of the insulin receptor (IR) [40, 41]. Our review focuses on a conserved segment of the B 
chain—the conserved “aromatic triplet” PheB24, PheB25 and TyrB26 [42]—as the thread of a 
remarkable story. The positions of these residues in the zinc insulin hexamer (T6) are shown 
in Figure 2A, and their positions in the dimer are shown in Figure 2B. Interest in the 
contribution of the aromatic triplet to the structure and function of insulin thus began with 
the first crystal structure of insulin, deepened with the first discovery of mutations in the 
insulin gene associated with diabetes mellitus [43–46] and continues in ongoing efforts to 
decipher the structure of the hormone-receptor complexes [47, 48], including by single-
particle cryo-electron microscopy [49].
2 | CRYSTAL STRUCTURES OF INSULIN
The 1969 crystal structure of insulin (then designated 2-Zn insulin and now classified as a 
T6 hexamer [50]) was the among the first set of protein structures to be determined (for 
reviews, see [6, 51]). Each of these early structures (spanning globins, ribonucleases and 
proteases) uncovered a new aspect of protein structure and its relationship to function. These 
features were to inform general principles of protein folding and assembly in the ensuing 
decades.
The 2-Zn insulin structure depicted a 32-point-group hexameric self-assembly whose dimer-
related interfaces contained a short anti-parallel β-sheet (Fig. 2C) and whose trimer-related 
interface was stabilized by histidine-mediated 2-zinc-ion coordination [9, 10]. Formation of 
these interfaces concealed extensive non-polar surfaces that would otherwise be exposed to 
solvent in an isolated protomer. The specific role of zinc ions in the structure of the insulin 
hexamer motivated continuing studies of zinc transporters in the cell biology of insulin 
storage within the secretory granules of pancreatic β-cells [52–54].
Crystal structures of zinc-free insulin dimers by Caspar and colleagues demonstrated that the 
T2 substructure in the 2-Zn insulin hexamer does not require hexamer assembly or zinc-ion 
coordination [29, 55].
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2.1 | The TR Transition
This original T6 structure contained a dimer in the crystallographic asymmetric unit, with 
the hexamer defined by a crystallographic three-fold symmetry axis. The two protomers 
within the dimer (designated molecules 1 and 2) exhibited subtle differences. More dramatic 
differences were subsequently observed in the 1976 crystal structure of “4-Zn” insulin [27] 
in which high concentrations of NaCl induced a conformational change to yield the T3R3 
hexamer [6, 56]. The T→R transition entailed N-terminal extension of the B-chain α-helix; 
cylinder models of the constituent TR dimer are shown in Figure 3. Subtle differences were 
also observed in this transition, including (i) in the conformation of the A7-B7 disulfide 
bridge, (ii) rotation and reorientation of the A1-A8 α-helix, and (iii) a slight displacement of 
the B24-B28 β-strand relative to A chain such that an inter-chain hydrogen bond (B25 NH…
O=C A19) is broken. The latter feature foreshadowed the frank displacement of the B-chain 
β-strand on receptor binding as described below (Section 3).
Comparison of the 2-Zn and 4-Zn structures provided a model for analysis of the long-range 
transmission of conformational change in a protein assembly [56] and inspired speculation 
regarding which structure (T or R) might best inform structure-activity relationships [6]. One 
study exploited a key aspect of this transition: a change in the conformation of an invariant 
glycine at position B8 (purple circles in Figure 3) from the right side of the Ramachandran 
plot in the T-state β-turn (B7-B10) to the left side to reside within the canonical α-helical 
island as in the R state [60]. Stabilization of the T state through substitution of D-Ala at B8 
impaired binding to the IR by at least 100-fold [60].
The T6→T3R3 transition was “completed” in 1989 through the discovery of R6 zinc insulin 
hexamers by G.G. Dodson and colleagues [28]. The conformational plasticity of insulin in 
the crystalline state (i.e., through the series of structures T6→T3R3→R6) motivated 
molecular-dynamics (MD) simulations [61–64] and NMR studies in solution [32–39]. The 
latter demonstrated that the predominant conformation of the hormone as a monomer in 
solution (the physiologic state in the bloodstream) closely resembles the crystallographic T 
state (Figure 4). Such studies exploited engineered insulin monomers to circumvent 
confounding effects of self-association [59]. In Section 3 we will shall see how this 
flexibility is exploited to achieve the novel receptor-bound structure of the hormone.
2.2 | The Aromatic Triplet
The sequence of the B chain is notable for the invariance of consecutive phenylalanine 
residues at positions B24 and B25 (red and green in Figure 5) and for the broad conservation 
of tyrosine at position B26 (violet). (Divergent rodent sequences may contain ArgB26 or 
SerB26, substitutions likely to preserve activity [67].) The conserved aromatic triplet is part 
of a β-strand within a dimer-related anti-parallel β-sheet (B24-B28; Figure 2C). In the 
T6→T3R3→R6 series of hexameric structures the side chains of PheB24 and TyrB26 (red and 
violet in Figure 6) participate in similar structural interactions whereas the position of 
PheB25 is variable and more peripheral to the hydrophobic core (green). The short-B-chain 
β-strands follow the B20-B24 β-turn, which contains conserved glycines at B20 and B23 
(canonical β-turn positions 1 and 4) [68].
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The aromatic side chains of PheB24, PheB25 and TyrB26 contribute to an extensive non-polar 
surface of the insulin monomer (Figure 7). This surface is engaged at the dimer interface in 
crystallographic dimers and hexamers [6, 51]. The side chains of the aromatic triplet thus 
occupy distinct structural environments in the insulin monomer and are associated with 
marked differences in structure activity relationships. Interested in these positions was 
stimulated in the 1980s by the discovery (by Steiner and his colleagues [including Howard 
S. Tager and Arthur H. Rubenstein] at the University of Chicago) of mutations at B24 and 
B25 in patients with diabetes mellitus [46].
Position B24.—The aromatic ring of PheB24 lies within a crevice such that one face seals 
the hydrophobic core and the other exposed to solvent. The ring contacts the methyl groups 
of LeuB15 and the β-protons of CysB19 as a conserved aspect of B-chain super-secondary 
structure. All natural amino-acid substitutions—with the anomalous exception of Gly—
impair receptor binding [69, 70]. Even substitution of PheB24 by its near-isostere Tyr impairs 
IR binding by at least tenfold [70, 71]. SerB24 is a clinical mutation, known as insulin Los 
Angeles [72].
The native activity of GlyB24-insulin may reflect a “register shift” in which PheB25-TyrB26 
take the place of PheB24-PheB25 with extrusion of a five-residue non-canonical turn 
(GERGG; residues B20-B24) [39]. An analogous shift may rationalize the enhanced affinity 
of non-standard insulin analogs containing D-amino-acid substitutions at B24 [38, 39, 73]. 
In such models the role of TyrB26 is taken by ThrB27 in general accordance with divergent 
rodent sequences (Figure 5 above).
Position B25.—The B25 side chain is less well ordered in solution; its aromatic 
resonances exhibit motional narrowing and fewer inter-residue nuclear Overhauser 
enhancements (NOEs) contacts relative to those of B24 or B26. Studies by the late H.S. 
Tager and his then-MD-PhD student Raghu Mirmira (now Director of the Diabetes Center 
and Professor of Medicine at the Indiana University School of Medicine) established that a 
broad range of aromatic residues are tolerated by the IR, including β-naphthyl-alanine. A 
general requirement was established for a trigonal γ-carbon, a shared feature of active 
aromatic substituents. LeuB25, found as a clinical mutation known as insulin Chicago [74] 
and containing a tetrahedral γ-carbon, impairs receptor binding by at least 50-fold [75, 76].
Position B26.—TyrB26 lies in part within a crevice between the A- and B chains, 
contacting the conserved side chains of ValB12, IleA2 and ValA3. This “closed” conformation 
thus conceals key aspects of the receptor-binding surface as inferred from mutagenesis and 
visualized in Section 3 through crystallographic studies of model hormone-receptor 
complexes. Although stabilization of the closed conformation by TyrB26 is not required for 
biological activity, it protects the free hormone from physical degradation [67].
Residue-specific photo-cross-linking studies, employing para-azido-Phe (Pap) as a photo-
activatable probe, implied that residues B24-B26 each pack at the hormone-receptor 
interface. Domain mapping of photo-products demonstrated that PapB24 and PapB26 photo-
cross-linked to the L1 domain of the IR α-subunit [77] whereas PapB25 contacted the C-
terminal fragment of the α-subunit [78]. To our knowledge, the use of Pap as a short and 
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rigid residue-specific photo-probe in insulin was first demonstrated by Steiner in 
collaboration with Katsoyannis [78]. Rigorous peptide mapping of PapB25-photo-products 
by Kurose et al. [78] (exploiting mass-spectrometric methods) provided the first 
identification of the conserved αCT motif in the IR ectodomain as a critical hormone-
binding element; its central structural role is highlighted in Section 3. Although 
incompletely visualized in electron-density maps, physical evidence that αCT functions in 
trans within the IR (αβ)2 dimer was provided by bifunctional Pap derivatives of insulin 
containing photo-probes at opposite surfaces [41].
Modifications at A2 and A3—sites partially concealed by the C-terminal segment of the B 
chain in the closed state—are also associated with markedly impaired activities [79, 80]. 
Even such subtle aliphatic substitutions as IleA2→allo-Ile (i.e., inversion of β-carbon 
chirality within the A2 side chain) [81] or substitution ValA3→Leu (insulin Wakayama [44]) 
cause profound defects in IR binding. In the following section we describe how detachment 
of the aromatic triplet at the receptor surface unmasks these A-chain residues. The latter are 
critical to receptor engagement via conserved αCT contacts.
3 | INTERACTION OF THE AROMATIC TRIPLET WITH THE RECEPTOR’S 
PRIMARY INSULIN-BINDING SITE.
3.1 | STRUCTURE OF THE INSULIN RECEPTOR ECTODOMAIN
In order to understand the remarkable role played by the aromatic triplet of insulin in 
mediating both hormone storage and receptor activation, it is appropriate to provide an 
overview of the structural biology of the insulin receptor itself. The receptor is a member of 
the modular receptor tyrosine kinase (RTK) family [82, 83]; two other members belong to 
the same sub-family of RTKs, namely, the type 1 insulin like growth factor receptor 
(IGF-1R) [82] and the IR-related receptor (IRR) [84]. These three receptors are distinct from 
other RTKs in that they are disulfide-linked homodimers, whereas the others are monomers. 
Conserved modules in the IR are shown in Figure 8.
The sequence of the human IR was determined in 1985 [82, 83]. The mature form of the 
receptor is a disulfide-linked (αβ)2 homodimer, formed by furin processing of disulfide-
linked pro-receptor polypeptides into α- and β chains. Within the insulin receptor 
homodimer, a single disulfide bond links each α chain to its β chain partner and at least two 
disulfide bonds cross-link the α chains to each other [85].
The receptor is heavily glycosylated: thirteen glycans are N-linked to each α chain and four 
to each β chain [86], and six glycans are O-linked to each β chain [87]. The human insulin 
receptor occurs as two splice variants, termed IR-A and IR-B, respectively, with IR-A 
isoform lacking (and IR-B isoform retaining) the twelve amino-acid protein product of exon 
11 [88]. IR-B is the predominant isoform in peripheral tissue and is responsible for 
metabolic signaling [89]. IR-A is the predominant isoform within fetal tissue and also within 
the adult brain. IR-A shows enhanced binding to insulin-like growth factors compared to IR-
B and is upregulated in certain cancers [89].
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The 3D structure of the IR extracellular region (its “ectodomain”) was derived from X-ray 
analysis of a crystal of the isolated ectodomain in complex with four Fab fragments; the 
latter were attached to the ectodomain fragment in order to overcome the hindrance posed to 
crystallization by the extensive N-linked glycosylation [90]. Within this structure, the extra-
cellular component of each αβ chain pair was revealed to have the following domain 
organization [48] (describing from the N terminus of the α chain through to the C terminus 
of the β chain): a leucine-rich repeat domain (L1), a cysteine-rich region (CR), a second 
leucine-rich repeat domain (L2), and finally three fibronectin type III domains (FnIII-1, 
FnIII-2 and FnIII-3; see Figure 8).
Within the holo receptor, the FnIII-3 domain is followed by a transmembrane helical 
segment (TM), a juxtamembrane region, the tyrosine kinase domain (TK) and a C-terminal 
tail segment [90]. Domain FnIII-2 contains within its canonical CC’ loop [48] a segment of 
approximately 110 residues termed the insert domain (ID) that in turn contains the α/β furin 
processing site (Figure 8). The three-dimensional crystal structure of the ectodomain has a Λ 
shape, with each “leg” of the Λ containing the L1-CR-L2 module of one receptor monomer 
juxtaposed in an anti-parallel fashion against the (FnIII-1)-(FnIII-2)-(FnIII-3) module of the 
opposing receptor monomer [48, 90], placing the sites of membrane entry at ends of the 
respective “legs” of the assembly (Figure 9).
The “head” of the Λ-shaped assembly contains of the [L2-(FnIII-1)]2 module, the two 
FnIII-1 domain components of which are disulfide bonded to each other at residue Cys524. 
The ID domains are mostly disordered and lie within the interior of the Λ-shaped structure, 
except for a segment (termed αCT, located near the C terminus of the α chain) that 
assembles as an α helix on the central β sheet (termed L1-β2) of the L1 domain of the 
opposing receptor monomer [48, 91]. A single inter-α-chain disulfide bond connects 
residues Cys524 (within the CC’ loop of domain FnIII-1) [90, 91], and at least one inter-α-
chain disulfide bond occurs within the ID at the triplet Cys682-Cys683-(Ser684)-Cys685 
[48, 85]. Each α chain is linked to its β-chain counterpart by a disulfide bond between 
residues Cys647 (within the α-chain segment of the ID) and Cys860 (within domain FnIII-3; 
IR-A numbering) [85]. All remaining disulfide bonds are intra-chain and there is a single 
free cysteine residue within FnIII-3 (Cys872; IR-A numbering) [85]. It should be noted that 
the crystal contained an (IR-A)-based construct termed IRΔβ, which was engineered to 
remove the heavily glycosylated segment near the N terminus of the receptor β chain (again 
to reduce hindrance to crystallization).
The inter-domain interfaces (both intra-monomer and inter-monomer) within the above 
structure are sparsely packed, with the only exception being that between the L1 domain and 
the N-terminal region of its immediately downstream CR domain [48, 90]. These loosely-
packed interfaces are reminiscent of crystal packing interfaces, suggesting that all or some of 
them may disassemble upon insulin binding. However, this raises the question as to whether 
reported apo ectodomain structure has been modulated by Fab attachment and/or crystal 
lattice embedding. Two lines of evidence support the view that the Λ-shaped structure 
represents that adopted by the ectodomain in the context of a membrane-embedded holo 
receptor. First, recent negative-stain electron microscopy imaging of holo insulin receptor 
embedded in lipid nanodiscs show, at least qualitatively, that the Λ-shaped assembly concurs 
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with that observed in the nanodisc context [92] (Figure 10). Second, crystallographic 
analysis of the isolated and growth factor-free IGF-1R ectodomain reveals it to have a 
similar shape and domain assembly to that of the insulin receptor, albeit that the IGF-1R 
construct employed included the attachment of a pair of antibody Fv modules [93].
3.2 | STRUCTURE OF MODEL HORMONE-RECEPTOR COMPLEXES
Insulin binding to the IR displays complex kinetics, characterized by curvilinear Scatchard 
plots and negative cooperativity. The latter was demonstrated by accelerated dissociation of 
labeled insulin upon dilution with cold insulin [94–97]. Further, the accelerated dissociation 
of insulin is reduced at high cold-insulin concentration (> 1 μM). These data can be 
explained by a model wherein insulin binding involves the formation of a cross-link between 
two distinct sites (designated site 1 and site 2’) on the receptor, where ‘ is used here and 
throughout to denote—within the context being described—entities from the alternate αβ 
monomer. Site 1 is taken to be the higher-affinity (“primary”) binding site and site 2’ the 
lower-affinity (“secondary”) binding site. Insulin binding to one site 1 / site 2’ pair is then 
proposed to reduce the affinity of insulin for the alternate site 1’ / site 2 pair (negative 
cooperativity). The reduction in accelerated dissociation at high insulin concentrations is 
explained within this model by postulating that, under such conditions, three insulin 
molecules can bind to the homodimeric receptor: one cross-linking the site 1 / site 2’ pair 
with high affinity, one binding to site 1’ and one to site 2. Insulin binding independently to 
the latter two sites then abrogates both the formation of a high-affinity cross-link between 
sites 1’ and 2 and the reduction in affinity of the site 1 / site 2’ cross-link.
The complexities of the hormone receptor-binding kinetics taken together with the structural 
complexities of the receptor itself have confounded attempts to crystallize the ectodomain in 
complex with insulin. Partial success has thus come via another route, namely, by analysis of 
insulin bound to fragments of the ectodomain [40, 41]. The smallest receptor fragment know 
to bind insulin is the isolated two-domain L1-CR construct in the presence of an exogenous 
peptide segment spanning the receptor αCT helix [98], which together display nanomolar 
affinity for insulin and arguably reconstitute site 1. This tandem receptor element (L1-CR + 
αCT) has been termed the insulin “micro-receptor” (μIR) [41], in the same vein of 
nomenclature as the earlier terms “mini-receptor” (the receptor L1-CR-L2 module plus an 
exogenous αCT peptide [99, 100]) and “midi-receptor” (the receptor [L1-CR-L2-(FnIII-1)]2 
fragment wherein each constituent FnIII-1 domain is extended at its C terminus by the α-
chain component of the ID domain [98, 101].
An X-ray crystallographic structure of a μIR complex consisting of (i) receptor residues 1–
310 (an L1-CR fragment), (ii) an αCT peptide fragment spanning residues 704–719 of IR-A 
and (iii) human insulin, has been determined to a resolution of 3.5 Å [40, 41] (Figure 11).
This structure reveals conformational change both in insulin and in the αCT segment upon 
their engagement and dissection of the atomic details has led to significant structural insight 
into the insulin’s classical structure-activity relationships. The details of the insulin / insulin 
micro-receptor complex are as follow [40, 41].(i) The αCT helix, compared to its 
conformation within the apo ectodomain structure, has undergone restructuring upon the L1-
β2 surface (Figure 12). In particular, its axis is rotated ~30° to lie approximately at right 
Weiss and Lawrence Page 8
Diabetes Obes Metab. Author manuscript; available in PMC 2019 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
angles to the direction of the β strands. In addition, it has unwound at its N terminus and 
wound on at its C terminus; the resultant helix spans residues 705–715 rather than residues 
694–710.
(ii) The insulin B-chain helix (observed here to span residues B9-B20) lies on the C-terminal 
edge of the L1-β2 surface, packing adjacent and anti-parallel to the αCT helix. To allow 
such accommodation, insulin B-chain residues B24 to B27 fold away from the core of the 
hormone, with the direction of the polypeptide segment B24-B27 now being approximately 
perpendicular to the axes of the receptor αCT helix and insulin B-chain helix [41] (Figure 
13).
(iii) No crystallographic electron density is apparent in this structure for insulin B-chain 
residues beyond residue B27, suggesting a lack of specific interaction of these elements with 
the receptor. (iv) No indication is apparent in this structure that the N-terminal helical 
extension of the insulin B-chain helix is formed upon microreceptor engagement. (v) The 
side chains of the αCT residues His 710 and Phe714 engage the exposed hormone core 
directly, with that of Phe714 effectively occupying the position of the side chain of TyrB26 in 
receptor-free insulin (Figure 14).
3.3 | PACKING OF THE AROMATIC TRIPLET AT HORMONE-RECEPTOR INTERFACE
Upon displacement of the B-chain C terminus from the hormone core, the side chain of 
insulin residue PheB24 undergoes a rotameric re-configuration leaving the phenyl ring in 
effectively the same relative place within the hormone core that it occupies in receptor-free 
insulin (Figure 15). Such positioning buries insulin residue PheB24 within a large 
hydrophobic cavity formed by insulin residues TyrA19, CysA20, LeuB15, receptor αCT 
residue Phe714 and receptor L1 domain residues An15, Leu37 and Phe39 (Figure 16).
In contrast to the positioning of the side chain of PheB24, the side chains of residues PheB25 
and TyrB26 are largely exposed within the μIR complex. The side chain of residue PheB25 
engages the αCT residues Val715 and Pro718 and is otherwise positioned adjacent to that of 
insulin residue ThrB27 (Figure 17). The side chain of residue TyrB26 is rotated away from the 
hormone core, stacking parallel to the side chains of the receptor L1 domain residues Asp12 
and Arg14 (Figure 18).
Residue ThrB27 appears weakly ordered in the μIR complexes, with B chain residues beyond 
B27 almost completely disordered. The latter observation is consistent with the ability of 
these residues to tolerate significant mutation, chemical modification or deletion [6, 102].
4 | FUTURE PERSPECTIVES
A major challenge is posed by extension of present structures of model hormone-receptor 
complexes [47, 48] to the holo-receptor. Such progress is likely to require a series of 
structures, each representing a step in the complex mechanism of conformational change 
leading to signal propagation. A significant advance was recently obtained through single-
particle cryo-electron microscopy analysis of the insulin-ectodomain complex [49]. Because 
the isolated ectodomain lacks a single high-affinity site and because the present analysis 
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encompassed only ca. 10% of the images, it is not yet clear how the rearrangement of 
fibronectin-homology domains observed in the structure [49] relates to the structure of the 
free ectodomain [47, 48] or μIR complexes [40, 41]. Of particular interest will be 
understanding the connection between Site 2 as inferred from the cryo-EM structure [49] 
and Site 2 as defined by kinetic analysis of insulin analogs [96, 97]. We speculate that the 
aromatic triplet plays a critical role to initiate a series of conformational changes associated 
with the modular reorganization of the ectodomain on hormone binding.
The aromatic triplet of vertebrate insulins and insulin-like growth factors may not be 
essential for insulin-like ligands. The recent structure of a venom insulin-like protein from 
an invertebrate (Conus geographus) provides an example of a “miniature” insulin lacking the 
C-terminal β-strand of the B chain [103].It is possible that such minimal insulin scaffolds 
could provide templates for design of novel therapeutic insulins. The C. geographus ligand 
contains multiple post-translational modifications whose contributions to stability and 
activity will require characterization.
A key constraint in the pharmacology of insulin analogs is posed by chemical- and physical 
degradation [7, 18]. The receptor-bound open conformation of the hormone may be 
particularly susceptible to such degradation, including formation of amyloid (insulin 
fibrillation). A promising structure-based route to the engineering of ultra-stable analogs is 
provided by foreshortened C domains [104, 105]. In such single-chain insulins (SCIs) the 
aromatic triplet resides in a closed conformation—tethered by a foreshortened connecting 
peptide—and yet sufficient “play” is provided to enable its detachment on receptor binding. 
It would be of future interest to investigate crystal- or cryo-EM structures of SCI-receptor 
complexes as probes of the closed-open transition. In the context of this issue, dedicated to 
the late Prof. Steiner, it would be fitting if the B-C-A structure of proinsulin [22, 23] should 
find application in next-generation therapeutic insulin analogs.
We envisage that continuing characterization of an insulin-related superfamily, spanning 500 
million years in the natural history of both vertebrates and invertebrates, will provide an 
increasingly fertile model for studies of protein evolution. How and why particular amino 
acids are conserved are questions that cross from structural biology to cell biology and 
physiology. Whereas the structural origins of some evolutionary constraints (such as co-
conservation of critical hormone-receptor contacts) may be apparent in structures (e.g., of 
complexes at higher resolution), deciphering other constraints may require study of off-
pathway events, such as toxic protein misfolding [18–21]. Other residues may contribute to 
on-pathway folding efficiency and yet be dispensable once the native state is achieved.
Extant insulin sequences thus lie at the intersection of multiple explicit and implicit 
constraints (Figure 19). Many—and indeed perhaps most—residues in insulin are likely to 
play different roles at distinct stages in the hormone’s complex “life cycle”: dissecting these 
roles will require high-resolution analysis of conformational change in this remarkable 
protein from biosynthesis to function and degradation.
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Figure 1. 
Office of Prof. D.F. Steiner at the University of Chicago. Shown on table at front in 
plexiglass box is a plastic model of insulin as a crystallographic protomer. Inset at top right, 
Hodgkin and Steiner with matching molecular models. This figure was originally published 
in a remembrance of D.F. Steiner [12] and is reprinted here with permission of the authors. 
The molecular model is now on display as part of an historical collection in the Division of 
Endocrinology at the Pritzker School of Medicine. One of the authors (MAW) recalls many 
pleasant and stimulating discussions in this office during which Don references one or more 
side chains in this model. Often these included the aromatic triplet—PheB24, PheB25 and 
TyrB26—in light of their special role in the Hodgkin structure.
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Figure 2. 
Insulin self-assembly as defined in the 1969 crystal structure of insulin [9, 10]. (A) T6 (or 2-
Zn) insulin hexamer, (B) Constituent dimer and (C) anti-parallel C-terminal dimer-related β-
sheet (residues B24-b28; arrows) with the side chains of residues B24-B26 shown in red, 
green and violet, respectively. Coordinates were obtained from Protein databank entry 4INS.
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Figure 3. 
The two classical conformations of insulin: T and R. TR dimer as extracted from crystal 
structure of a T3R3 zinc insulin hexamer, first observed in the classical “4-Zn” crystal form 
[27]. The position of B8 is indicated by a purple circle within the B-chain helix (green), 
which comprises residues B9-B19 in the T state, B1-B19 in the R state (or B3-B19 in the 
“frayed” Rf state).
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Figure 4. 
1H-NMR spectroscopy defines T-like conformation of an engineered insulin monomer. 
Solution structure of DKP-insulin highlighting the aromatic triplet (PheB24, PheB25 and 
TyrB26) in brown relative to ValB12, LeuB15 and cysteine B19-A20 in blue. In this 
monomeric analog dimerization was impaired by the paired substitutions LysB28 and ProB29 
[57], and the trimer interface was disrupted by AspB10 [58, 59]. The A chain is shown in 
yellow, and B chain in orange (B1-B19) and brown (B20-B30).
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Figure 5. 
Conservation of the “Aromatic Triplet”: sequence alignment of residues B20-B30, which 
encompasses a β-turn (B20-B23), β-trand (B24-B28) and less well-ordered terminal residues 
(B29 and B30). Phe is invariant among vertebrate insulins at positions B24 (red) and B25 
(green) whereas Tyr is highly conserved at position B26 (lilac). The divergent insulin in the 
rodent O. degu is associated with insulin fibrillation of the islet, leading to β-cell death and 
senile DM [65, 66].
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Figure 6. 
Aromatic triplet at dimer interface. Stereo pairs showing PheB24 (red), PheB25 (green) and 
TyrB26 (violet) in dimer-related β-sheet in (A) T6 hexamer (B) T3Rf3 hexamer and (C) R6 
hexmer. Coordinates were obtained from Protein Databank entries 4INS, 1TRZ and 1ZNJ, 
respectively. Dotted lines indicate β-sheet-related hydrogen bonds.
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Figure 7. 
T-state structure of insulin. Aromatic triplet is part of an extensive non-polar surface of the 
insulin monomer. (A) Stick representation highlighting side chains of PheB24 (red), PheB25 
(gray; not labeled at right), and TyrB26 (purple at upper right) relative to α-helical residues 
ValB12 (blue), LeuB15 (green) and TyrB16 (purple at lower left). The internal disulfide bridge 
of cystine B19-A20 is shown in yellow. The A chain is shown in dark gray, and B chain 
otherwise shown in light gray. (B) Corresponding dot-surface representation of the 
highlighted residues with neighboring residues B20-B23, B25 and B27 in light gray; A20-
A21 is dotted in dark gray.
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Figure 8. 
Primary structure of the insulin receptor (αβ)2 homodimer. Ll: first leucine-rich repeat 
domain; CR: cysteine-rich region; L2:second leucine-rich repeat domain; Fnlll-1 , Fnlll-2 
and Fnlll-3: first, second and third fibronectin type III domains; ID: insert domain (IDα: α-
chain component; IDβ: β-chain component); αCT: C-terminal segment of the receptor α 
chain, TM: trans-membrane segment; JM: juxta-membrane segment; TK: tyrosine kinase 
domain; C-tail: C-terminal tail of the receptor β chain. Inter-chain disulfide bonds are 
indicated by solid green lines, individual N-linked glycosylation sites by “Y” symbols and 
the location of the O-linked glycosylation segment by an orange “V” symbol.
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Figure 9. 
Crystal structure of the insulin receptor (αβ)2 ectodomain. One αβ monomer is shown in 
ribbon representation (foreground), the other in molecular surface representation 
(background). The coloring of domains is as in Panel A. Part of IDα is indicated as a dashed 
line (foreground monomer only), as it was disordered within the crystal. The schematic is 
based on PDB entry 4ZXB [48].
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Figure 10. 
Negative-stain transmission electron microscopy images of holo insulin receptor embedded 
in nanodiscs [92]. The left-hand panel is an image of the receptor in an insulin-free state, the 
right-hand panel is an image of the receptor in an insulin-bound state, with the panels 
underneath each offering an interpretation of the respective images above. The 
correspondence of the Λ-shaped particle in the left-hand panel to those of that of the crystal 
structure of the isolated ectodomain is apparent. The right-hand panels show the closing of 
the receptor legs upon addition of insulin and a likely folding out of the L1-CR-L2 modules. 
Republished with permission of the Rockefellar University Press, from “Journal of Cell 
Biology, Gutmann et al., v217, p1643 (2018)”; permission conveyed through Copyright 
Clearance Center, Inc. [92].
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Figure 11. 
Interaction of insulin with the receptor’s primary binding site. Schematic shows overall 
organization of the insulin microreceptor (μIR, the L1-CR module + an αCT peptide) in 
complex with insulin [40, 41]. The schematic is based on PDB entry 4OGA [41].
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Figure 12. 
Conformational change in the primary binding site of the IR upon insulin binding. 
Schematic shows rotation and re-organization of αCT on the surface of domain L1 upon 
insulin binding. The schematic is based on PDB entries 4ZXB [48] and 4OGA [41].
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Figure 13. 
Folding away from the hormone core of insulin residues B24-B30 upon engagement with 
μIR. The receptor-bound insulin B chain is in black and A chain in white, overlaid with the 
B chain of the free hormone in cyan. The schematic is based on PDB entries 4INS [6] and 
4OGA [41].
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Figure 14. 
Details of the interaction of αCT residue His710 and Phe714 with the hormone core. The 
insulin A chain is in white with green side chains, the B chain is in black with light blue side 
chains. The receptor L1 domain is in tan and the receptor αCT helix is in magenta. The 
schematic is based on PDB entry 4OGA [41].
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Figure 15. 
Re-positioning of insulin residues B24-B27 upon engagement with μIR. The receptor-
bound insulin B chain is in black and A chain in white, overlaid with the B chain of the free 
hormone in cyan. The schematic is based on PDB entries 4INS [6] and 4OGA [41].
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Figure 16. 
Atomic environment of PheB24 within the Site 1 μIR complex. Schematic shows all side 
chains of all residues within 4 Å of that of insulin PheB24 (unlabeled, orange). Insulin A 
chain is in white, insulin B chain is in black, L1 domain of the insulin receptor is in tan, 
αCT segment of the insulin receptor is in magenta. Receptor residues have underlined labels 
whereas insulin residues are in normal font. The schematic is based on PDB entry 4OGA 
[41].
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Figure 17. 
Atomic environment of PheB25 within the Site 1 μIR complex. Schematic shows all side 
chains of all residues within 4 Å of that of insulin PheB25 (unlabeled, orange). Color and 
labeling schemes are otherwise as in Figure 12. (q.v.). The schematic is based on PDB entry 
4OGA [41].
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Figure 18. 
Atomic environment of TyrB26 within the Site 1 μIR complex. Schematic shows all side 
chains of all residues within 4 Å of that of insulin TyrB26 (unlabeled, orange). Color- and 
labelling schemes are otherwise as in Fig. 12. (q.v.). The schematic is based on PDB entry 
4OGA [41].
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Figure 19. 
Evolutionary constraints and insulin fibrillation: Venn diagram showing intersection of 
multiple constraints: function, foldability, misfolding and assembly.
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